Omadacycline
CAS: 389139-89-3
Ref. 3D-PQA13989
| Tamanho indefinido | Descontinuado | ||
| 1mg | Descontinuado | ||
| 5mg | Descontinuado | ||
| 10mg | Descontinuado | ||
| 25mg | Descontinuado |
Informação sobre produto
Nome:
Omadacycline
Sinónimos:
- (4S,4aS,5aR,12aS)-4,7-Bis(dimethylamino)-9-[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
- 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-
- Amadacycline
- Bay 73-7388
- Mk 2764
- Ptk-0796
Descrição:
Omadacycline is a p-glycoprotein inhibitor that has been shown to be effective against antibiotic-resistant strains of bacteria. It is active against aerobic, anaerobic, and facultative bacteria and has activity against both Gram-positive and Gram-negative organisms. Omadacycline was approved by the FDA in 2017 for the treatment of complicated skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA) or multidrug-resistant Enterobacteriaceae. This drug binds to bacterial ribosomes, inhibiting protein synthesis and stopping cell division. Omadacycline has been shown to be safe and well tolerated in clinical trials.
Aviso:
Os nossos productos estão destinados exclusivamente para uso em laboratório. Para qualquer outra aplicação, por favor entre em contacto.
Marca:
Biosynth
Armazenamento a longo prazo:
Notas:
Propriedades químicas
Peso molecular:
556.65 g/mol
Fórmula:
C29H40N4O7
Pureza:
Min. 95%
MDL:
Ponto de fusão:
Ponto de ebulição:
Ponto de inflamação:
Densidade:
Concentração:
EINECS:
Merck:
Código HS:
